GSK plc (NYSE:GSK) Shares Bought by RKL Wealth Management LLC

RKL Wealth Management LLC increased its holdings in GSK plc (NYSE:GSK) by 12.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,024 shares of the pharmaceutical company’s stock after buying an additional 919 shares during the quarter. RKL Wealth Management LLC’s holdings in GSK were worth $271,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Sunbelt Securities Inc. grew its stake in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares during the period. Indiana Trust & Investment Management Co grew its stake in shares of GSK by 200.0% during the 4th quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust acquired a new stake in shares of GSK during the 4th quarter worth approximately $26,000. ST Germain D J Co. Inc. grew its stake in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after purchasing an additional 522 shares during the period. Finally, Sierra Ocean LLC acquired a new stake in shares of GSK during the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Trading Up 2.0 %

Shares of GSK opened at $40.08 on Friday. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm’s fifty day moving average is $35.47 and its two-hundred day moving average is $37.17. The stock has a market cap of $83.07 billion, a PE ratio of 25.21, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Research analysts forecast that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 3.92%. GSK’s payout ratio is presently 98.74%.

Analysts Set New Price Targets

A number of research firms recently issued reports on GSK. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and dropped their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, GSK presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.